Latest news with #RSV-related
Scoop
4 days ago
- Health
- Scoop
Education Suffers Amid DR Congo Violence, WHO Greenlights RSV Vaccines, More Hurricanes Ahead For Haiti
According to UN Children's Fund, UNICEF, more than 290 schools have been damaged or destroyed in Ituri this year alone, bringing the total number of out-of-school children in the province to over 1.3 million. Protection crisis Between January and April 2025, a surge in violence displaced more than 100,000 people – half of them children. During this period, reported cases of abduction, maiming, sexual violence, and the recruitment and use of children by armed groups rose by 32 per cent compared to the same timeframe last year. John Adbor, UNICEF's representative in the DRC, referred to the situation as a 'protection crisis', stating: 'Violence and conflict are shattering children's right to learn – putting them at far greater risk of being recruited by armed groups, exploited, and abused.' 'The needs are immense, and our resources are not enough,' Mr. Adbor added, referring to UNICEF's emergency response in the region. With more than 1.8 million conflict-affected children now out of school across the DRC, UNICEF is prioritising mental health and psychosocial support through child-friendly spaces, reintegration of children formerly associated with armed groups, and treatment for acute malnutrition. WHO approves two new vaccines to protect infants from RSV Respiratory syncytial virus (RSV) is the leading cause of severe lung infections in young children globally, resulting in approximately 100,000 deaths each year among children under the age of five. Alarmingly, 97 per cent of these deaths occur in low and middle-income countries. Although RSV can infect people of all ages, 'it is especially harmful to infants, particularly those born prematurely,' said Kate O'Brien from the World Health Organization (WHO). Around half of all RSV-related deaths occur in babies younger than six months. New immunisation products On Friday, WHO issued recommendations for two new immunisation tools: a maternal vaccine, administered to pregnant women in their third trimester to protect their newborns; and a long-acting antibody injection for infants, which begins to protect within a week of administration and lasts for at least five months. Considering the global burden of severe RSV illness in infants, WHO recommends that all countries adopt either the maternal vaccine or the antibody injection as part of their national immunisation strategies. 'These RSV immunisation products can transform the fight against severe RSV disease, dramatically reduce hospitalisations and deaths, and ultimately save many infant lives worldwide,' said Ms O'Brien. Dire hurricane forecasts compound Haiti woes UN humanitarians have raised alarm over Haiti's heightened vulnerability to natural disasters, warning that the country's limited capacity to respond could be severely tested during the 2025 hurricane season – forecast to be significantly more intense than average across Latin America and the Caribbean. Running from June to November, the upcoming season poses a serious threat to the impoverished island nation, where economic crisis, ongoing gang-related violence and rampant insecurity have already displaced over one million people. Displacement sites at risk More than 200,000 people are currently living in displacement sites across the country, many of which are situated in flood-prone areas. Lacking proper shelter, drainage and sanitation, these camps 'leave families acutely vulnerable to storms,' said UN Spokesperson Stéphane Dujarric. The UN Office for the Coordination of Humanitarian Affairs (OCHA) is working with national authorities and humanitarian partners to prepare for the hurricane season. Ongoing efforts include contingency planning, mapping of high-risk areas – particularly displacement sites – and strengthening early warning systems. However, humanitarian access remains limited, and preparedness is severely hindered by the lack of pre-positioned supplies throughout the country. This is a 'direct consequence of underfunding,' said Mr. Dujarric, adding that 'funding remains a major obstacle' to the UN's emergency response in Haiti.
Yahoo
6 days ago
- Business
- Yahoo
Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts 2019-2024, 2024-2029F, 2034F
This Abrysvo or Arexvy market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market. Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Abrysvo or Arexvy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to growth during the historic period can be attributed to an aging population, the launch of vaccination programs, increased awareness of respiratory illnesses, government health initiatives, and seasonal respiratory illness outbreaks. Major companies operating in the abrysvo or arexvy market are Pfizer Inc. and GlaxoSmithKline plc (GSK). North America was the largest region in the abrysvo or arexvy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast during the market's forecast period can be attributed to the expanding elderly population, increased vaccine access and global distribution, a greater emphasis on preventative healthcare, a rising incidence of respiratory infections, and improved healthcare policies and coverage. Key trends in the forecast period include advancements in vaccine technology, personalized medicine, integration of wearable health technology, innovations in vaccine delivery, cold chain logistics, and smart growing prevalence of respiratory syncytial virus (RSV) infections is expected to drive the growth of the abrysvo or arexvy market in the future. RSV infections are caused by the respiratory syncytial virus, a common virus that primarily affects the respiratory system, leading to mild cold-like symptoms in most individuals, but potentially severe illness in infants, older adults, and those with weakened immune systems. The increasing prevalence of RSV infections is fueled by the virus's highly contagious nature, seasonal outbreaks, lack of widespread immunity, and heightened vulnerability among populations such as infants and the elderly. Abrysvo helps address this issue by providing targeted vaccines to protect high-risk groups, such as older adults and infants, from severe RSV-related illnesses. For example, in October 2024, the Centers for Disease Control and Prevention (CDC), a US-based health protection agency, reported that during the 2024-25 season, the hospitalization rate for RSV was 3.2 per 100,000 individuals. As a result, the rising prevalence of RSV infections is driving the growth of the abrysvo or arexvy increase in healthcare expenditure is also expected to support the growth of the abrysvo or arexvy market. Healthcare expenditure refers to the financial investment made by governments, private insurers, and individuals into the healthcare system to enhance and expand medical services. This rise in healthcare expenditure is driven by factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, a higher demand for healthcare services, and rising costs of pharmaceuticals and treatments. Increased healthcare spending provides more financial resources for advanced treatment options, including biologic therapies, which benefits the Abrysvo or Arexvy market. For instance, in May 2023, the Office for National Statistics, a UK government department, reported that healthcare spending in the UK increased by 5.6% from 2022 to 2023, compared to a growth rate of 0.9% in 2022. The total healthcare expenditure in the UK amounted to approximately $317.63 billion (£292 billion) in 2023. Therefore, the rise in healthcare expenditure is contributing to the growth of the abrysvo or arexvy market.A key trend in the abrysvo or arexvy market is the expansion of age indications to extend the vaccine's use to a broader range of age groups, thereby enhancing public health protection and increasing market reach. The bivalent RSV prefusion F (RSVpreF) vaccine is designed to provide immunity against respiratory syncytial virus (RSV), targeting both the RSV-A and RSV-B subtypes. For example, in October 2024, Pfizer Inc., a US-based pharmaceutical company, received FDA approval for ABRYSVO (RSV Vaccine), a bivalent RSVpreF vaccine, to prevent lower respiratory tract disease in adults aged 18 to 59 at increased risk, thus broadening its indication to a wider adult population. It remains the only approved RSV vaccine for pregnant individuals between 32 and 36 weeks of gestation to protect infants from birth to 6 Topics Covered: 1. Executive Summary2. Abrysvo or Arexvy Market Characteristics3. Abrysvo or Arexvy Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Abrysvo or Arexvy Market Trends and Strategies5. Abrysvo or Arexvy Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Abrysvo or Arexvy Growth Analysis and Strategic Analysis Framework6.1. Global Abrysvo or Arexvy PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Abrysvo or Arexvy Market Growth Rate Analysis6.4. Global Abrysvo or Arexvy Historic Market Size and Growth, 2019-2024, Value ($ Million)6.5. Global Abrysvo or Arexvy Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Million)6.6. Global Abrysvo or Arexvy Total Addressable Market (TAM)7. Global Abrysvo or Arexvy Pricing Analysis & Forecasts8. Abrysvo or Arexvy Market Segmentation8.1. Global Abrysvo or Arexvy Market, Segmentation by Clinical Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Respiratory Syncytial Virus (RSV) Prevention Infant Protection 8.2. Global Abrysvo or Arexvy Market, Segmentation by Age Group, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Adults (18-59 years) Older Adults (60+ years) Pregnant Individuals (32-36 weeks of gestation) 8.3. Global Abrysvo or Arexvy Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million Healthcare Providers Pregnant Individuals High-Risk Adults 9. Global Abrysvo or Arexvy Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Abrysvo or Arexvy Market Regional and Country Analysis10.1. Global Abrysvo or Arexvy Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Million10.2. Global Abrysvo or Arexvy Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ MillionCompanies Featured Pfizer Inc. GlaxoSmithKline plc (GSK) For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-05-2025
- Health
- Yahoo
RSV is common and sometimes dangerous. Here's what to know.
Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related RSV spikes are in the news, the virus is actually just as worrisome in older adults. In fact, while more than 2 million children under age 5 make an RSV-related outpatient visit each year with some 58,000 to 80,000 of them ending up in the hospital, far more older adults infected with the viral disease are hospitalized, per surveillance data from the U.S. Centers for Disease Control and Prevention. The organization notes that between 100,000 and 150,000 adults age 60 and older end up being hospitalized because of RSV each year. Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated. RSV is a respiratory virus that infects the nose, throat and lungs. While people with larger airways and strong immune systems aren't as adversely affected by the infection, young children and older adults often are. The main reason infants and toddlers struggle is "due to the size of their airways," says Dr. David Hill, a North Carolina-based pediatrician and a spokesperson of the American Academy of Pediatrics. "RSV clogs up the smallest breathing tubes (known as bronchioles) in the child's lungs – and the smaller the lungs, the more severe the effects." He adds that older adults are similarly affected "due to age-related loss of lung tissue and diminished immune function and chest muscle strength." The same can be said for people with certain lung conditions such as asthma or COPD. Airway blockage and reduced lung function can diminish a vulnerable person's ability to eat, drink or even breathe, which is why nutrients and fluids may need to be administered intravenously with oxygen assistance often also becoming necessary. RSV is spread from person to person, with the virus "often hitching a ride on a sneeze, a kiss or a shared toy," says Hill. Once germs are inhaled either directly from expelled respiratory droplets or by touching an infected surface, then touching one's eyes, nose or mouth, it usually takes between four to six days for symptoms to appear. Noted: Nearly 1 in 10 Americans have asthma. Here's what causes it. Common RSV symptoms in many people include "a runny nose, cough, sneezing and fever – basically mild cold-like symptoms that are mostly contained to the upper respiratory tract," says Dr. Alison Mitzner, a board-certified pediatrician in New York City and the author of "Calm and Confident Parenting." In this stage, RSV can be hard to distinguish from the common cold or other respiratory viruses like COVID-19 or influenza. But things change when the virus moves from the upper respiratory system to the lower respiratory tract. Once in the trachea, bronchioles and lungs, "RSV can wreak havoc and cause symptoms like wheezing and difficulty breathing and lead to infections like bronchiolitis or pneumonia," Mitzner says. In toddlers, some of the earliest signs that RSV has infected the lower respiratory system are a diminished interest in eating and decreased vocalizations such as crying, cooing or speaking, says Hill. "You may also see the skin pulling between their ribs, under their rib cage, or over the collarbones and the base of the neck as they struggle to breathe," he adds. "And you may notice a grunting sound with each breath, the nose flaring when they inhale or the head bobbing up and down with breathing." As oxygen and nutrient intake diminish, energy levels quickly follow and infected children often become sleepy or unresponsive. "Children with any of these symptoms should be seen immediately by a medical provider," advises Hill. Ditto for older adults or immunocompromised people who have recently had cold-like symptoms and are now struggling to breathe, experiencing dizziness or confusion or are eating/drinking less. Feeling dizzy? It could be dehydration. Here's what to know. RSV that has moved from the upper to lower respiratory tract in vulnerable people is often treated in hospital settings with the primary goal being to help with oxygen assistance and nutrient intake until the body kills the virus. Professional care also sometimes includes "airway clearance with the help of respiratory therapists," says Hill. "Albuterol or saline nebulizer treatments are also sometimes recommended, but few patients respond to them." When RSV symptoms remain mild, symptoms can be treated at home. "Common at-home treatments and remedies include nasal saline with suctioning, using a cool-mist humidifier, frequent fluids and feedings to ensure hydration and taking acetaminophen or ibuprofen (if older than 6 months) for fever," says Mitzner. For most people, RSV symptoms "tend to peak between days three to five of the illness," she adds, "but may last up to two weeks." This article originally appeared on USA TODAY: How to treat RSV
USA Today
08-05-2025
- Health
- USA Today
RSV is common and sometimes dangerous. Here's what to know.
RSV is common and sometimes dangerous. Here's what to know. Show Caption Hide Caption Here's how to prepare for this cold and flu season Here are some ways to prepare for this cold and flu season as four illnesses currently circulate the country. Respiratory Syncytial Virus or RSV is one of the most common respiratory viruses circulating today. Often thought of as only being dangerous to babies and toddlers due to how often child-related RSV spikes are in the news, the virus is actually just as worrisome in older adults. In fact, while more than 2 million children under age 5 make an RSV-related outpatient visit each year with some 58,000 to 80,000 of them ending up in the hospital, far more older adults infected with the viral disease are hospitalized, per surveillance data from the U.S. Centers for Disease Control and Prevention. The organization notes that between 100,000 and 150,000 adults age 60 and older end up being hospitalized because of RSV each year. Here's what RSV is, why it especially impacts the youngest and oldest members of society and how it is usually treated. What is RSV? RSV is a respiratory virus that infects the nose, throat and lungs. While people with larger airways and strong immune systems aren't as adversely affected by the infection, young children and older adults often are. The main reason infants and toddlers struggle is "due to the size of their airways," says Dr. David Hill, a North Carolina-based pediatrician and a spokesperson of the American Academy of Pediatrics. "RSV clogs up the smallest breathing tubes (known as bronchioles) in the child's lungs – and the smaller the lungs, the more severe the effects." He adds that older adults are similarly affected "due to age-related loss of lung tissue and diminished immune function and chest muscle strength." The same can be said for people with certain lung conditions such as asthma or COPD. Airway blockage and reduced lung function can diminish a vulnerable person's ability to eat, drink or even breathe, which is why nutrients and fluids may need to be administered intravenously with oxygen assistance often also becoming necessary. RSV is spread from person to person, with the virus "often hitching a ride on a sneeze, a kiss or a shared toy," says Hill. Once germs are inhaled either directly from expelled respiratory droplets or by touching an infected surface, then touching one's eyes, nose or mouth, it usually takes between four to six days for symptoms to appear. Noted: Nearly 1 in 10 Americans have asthma. Here's what causes it. What are the symptoms of RSV? Common RSV symptoms in many people include "a runny nose, cough, sneezing and fever – basically mild cold-like symptoms that are mostly contained to the upper respiratory tract," says Dr. Alison Mitzner, a board-certified pediatrician in New York City and the author of "Calm and Confident Parenting." In this stage, RSV can be hard to distinguish from the common cold or other respiratory viruses like COVID-19 or influenza. But things change when the virus moves from the upper respiratory system to the lower respiratory tract. Once in the trachea, bronchioles and lungs, "RSV can wreak havoc and cause symptoms like wheezing and difficulty breathing and lead to infections like bronchiolitis or pneumonia," Mitzner says. In toddlers, some of the earliest signs that RSV has infected the lower respiratory system are a diminished interest in eating and decreased vocalizations such as crying, cooing or speaking, says Hill. "You may also see the skin pulling between their ribs, under their rib cage, or over the collarbones and the base of the neck as they struggle to breathe," he adds. "And you may notice a grunting sound with each breath, the nose flaring when they inhale or the head bobbing up and down with breathing." As oxygen and nutrient intake diminish, energy levels quickly follow and infected children often become sleepy or unresponsive. "Children with any of these symptoms should be seen immediately by a medical provider," advises Hill. Ditto for older adults or immunocompromised people who have recently had cold-like symptoms and are now struggling to breathe, experiencing dizziness or confusion or are eating/drinking less. Feeling dizzy? It could be dehydration. Here's what to know. How to treat RSV RSV that has moved from the upper to lower respiratory tract in vulnerable people is often treated in hospital settings with the primary goal being to help with oxygen assistance and nutrient intake until the body kills the virus. Professional care also sometimes includes "airway clearance with the help of respiratory therapists," says Hill. "Albuterol or saline nebulizer treatments are also sometimes recommended, but few patients respond to them." When RSV symptoms remain mild, symptoms can be treated at home. "Common at-home treatments and remedies include nasal saline with suctioning, using a cool-mist humidifier, frequent fluids and feedings to ensure hydration and taking acetaminophen or ibuprofen (if older than 6 months) for fever," says Mitzner. For most people, RSV symptoms "tend to peak between days three to five of the illness," she adds, "but may last up to two weeks."
Medscape
07-05-2025
- Health
- Medscape
Does Nirsevimab Help Prevent Severe RSV Infections?
Among 69 hospitalisations of infants for respiratory syncytial virus (RSV)–related lower respiratory tract infection (LRTI) in a Spanish study, 65.2% occurred despite the administration of nirsevimab. A large proportion of the hospitalised infants had high-risk conditions and needed oxygen support, with no significant differences observed between breakthrough and non-breakthrough cases. METHODOLOGY: Researchers conducted NIRSE-GAL, a prospective observational study between 2023 and 2024 across 14 public hospitals in Galicia, Spain. A total of 69 infants (median age at admission, 2.7 months; 56.5% boys) who received nirsevimab and were hospitalised for RSV-related LRTI were included. Cases were classified as breakthrough (n = 45) or non-breakthrough (n = 24). Breakthrough cases were defined as those in which nirsevimab was administered at least 7 days before admission with no observation of clinical symptoms compatible with RSV infection within 7 days post-administration and no RSV-positive test result in the 15 days before immunisation. Sociodemographic, clinical, and hospitalisation-related data were obtained and analysed. TAKEAWAY: The median length of hospital stay was 4 days among breakthrough cases. Among all hospitalised infants, 23.2% had high-risk conditions, 63.8% required oxygen support, 21.7% needed admission to the intensive care unit, and 15.9% received non-invasive mechanical ventilation. No significant differences in terms of these characteristics were found between breakthrough and non-breakthrough cases. The incidence of cases paralleled the RSV epidemic curve, suggesting that the efficacy of nirsevimab did not wane over time. IN PRACTICE: "During the first RSV season after the universal implementation of nirsevimab in Galicia (Spain), a large proportion of hospitalized infants had high-risk conditions, yet disease severity markers (oxygen need, ICU [intensive care unit] admission, NIVM [non-invasive mechanical ventilation]) were comparable between breakthrough and non-breakthrough cases," the authors wrote. "No signal of waning protection over time was observed among breakthrough cases, reinforcing the potential value of early, season-wide immunization," they added. SOURCE: This study was led by Angela Manzanares, Hospital Clínico Universitario de Santiago and University of Santiago de Compostela, Santiago de Compostela, Spain. It was published online on May 02 in the European Journal of Pediatrics . LIMITATIONS: The study had a small sample size, which may have reduced the statistical power and limited the application of complex analyses. Data were obtained only from public hospitals. DISCLOSURES: The NIRSE-GAL study received funding from Sanofi/AstraZeneca (through a research grant to the Healthcare Research Institute of Santiago) and a Framework Partnership Agreement between Consellería de Sanidad de la Xunta de Galicia and GENVIP-IDIS-2021-2024. Additional funding came from ISCIII, GAIN, ACIS, Consorcio Centro de Investigación Biomédica en Red de Enfermedades Respiratorias, the Galician Supercomputing Center, the Spanish Ministry of Science and Innovation, the Galician Government, and the European Regional Development Fund, the European Seventh Framework Programme for Research and Technological Development. Several authors reported acting as investigators in clinical trials for pharmaceutical companies, with honoraria paid to their institutions. Some also disclosed having consulting, advisory, or employment ties and possibly holding shares or stock options with various companies.
